PRINCETON, N.J., Dec. 6, 2012 /PRNewswire/ -- CoreLab Partners, Inc., a leading independent core lab providing centralized cardiac safety services and medical imaging assessment, has launched new imaging capabilities targeted at the utilization of independent central image review in the detection of early Alzheimer's disease.
"Recognizing the ongoing evolution of magnetic resonance imaging (MRI), positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging in dementia-related clinical trials, CoreLab Partners has put into place a team of knowledgeable experts combined with advanced technological tools to ensure current and emerging image assessment needs are met," stated Dr. Michael Woehler, President & CEO. "This exciting new capability is a natural extension of our industry-leading suite of imaging science solutions and marks a significant milestone in the utilization of scientifically validated tools designed to accurately quantify brain structure volumetric data," added Woehler.
Senior members of the CoreLab Partners' medical affairs team will be attending CBIs upcoming 6th Annual Alzheimer's Drug Development Summit to be held in Philadelphia, PA from December 11 – 12, 2012; please join us for this important industry event as the scientific community shares their future perspectives from the Dominantly Inherited Alzheimer's Network (DIAN).
About CoreLab Partners, Inc.
CoreLab Partners, with offices in North America, Europe and Asia, provides comprehensive medical image assessment and cardiac safety services to the pharmaceutical, biotechnology and medical device industries. An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with board certified, sub-specialty trained Radiologists, Cardiologists, nuclear medicine physicians and Oncologists. CoreLab Partners delivers disciplined solutions for the collection, analysis and management of patient images and cardiac safety & efficacy information during drug development. Driven by best-in-class science, emerging technologies and service quality, CoreLabs is a global leader providing imaging sciences in all major modalities complemented by service offerings in the conduct of automated ECG, Thorough QT, Holter Monitoring, Ambulatory Blood Pressure Monitoring and Pulse Wave Analysis.
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.
SOURCE CoreLab Partners, Inc.